Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Biodesix

Biodesix is a data-driven diagnostic solutions company operating in the healthcare sector, with a primary focus on lung disease. The company offers diagnostic tests that personalize patient care and improve disease detection, evaluation, and treatment, particularly in the context of lung cancer. Biodesix primarily serves physicians, researchers, and biopharmaceutical companies. It was founded in 2005 and is based in Boulder, Colorado.

Headquarters Location

2970 Wilderness Place Suite 100

Boulder, Colorado, 80301,

United States




Expert Collections containing Biodesix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biodesix is included in 1 Expert Collection, including Precision Medicine Tech Market Map.


Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Biodesix Patents

Biodesix has filed 61 patents.

The 3 most popular patent topics include:

  • rare diseases
  • classification algorithms
  • experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Electronic health records, Intensive care medicine, Respiratory therapy, Health informatics, Zoonoses


Application Date


Grant Date



Related Topics

Electronic health records, Intensive care medicine, Respiratory therapy, Health informatics, Zoonoses



Latest Biodesix News

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

Feb 16, 2024

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 February 16, 2024 at 06:01 am EST Share Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time. About Biodesix Biodesix is a leading diagnostic solutions company with a focus in lung disease. The company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting the time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit Note Regarding Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 6, 2023 or subsequent quarterly reports on Form 10-Q during 2023, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. View source version on Share

Biodesix Frequently Asked Questions (FAQ)

  • When was Biodesix founded?

    Biodesix was founded in 2005.

  • Where is Biodesix's headquarters?

    Biodesix's headquarters is located at 2970 Wilderness Place, Boulder.

  • What is Biodesix's latest funding round?

    Biodesix's latest funding round is IPO.

  • How much did Biodesix raise?

    Biodesix raised a total of $259.21M.

  • Who are the investors of Biodesix?

    Investors of Biodesix include Paycheck Protection Program, Crabtree Ventures, Meakem Becker Venture Capital, Birchview Capital, Innovatus Capital Partners and 8 more.

  • Who are Biodesix's competitors?

    Competitors of Biodesix include Dilon Technologies, ErleaDx, Upromise, Akonni Biosystems, Exagen and 7 more.


Compare Biodesix to Competitors


ProteoGenix is a leading antibody production company specializing in biologics discovery and development within the biopharmaceutical industry. The company offers a range of services including custom antibody generation, protein production, and gene and peptide synthesis. ProteoGenix primarily serves sectors such as therapeutic antibody development, diagnostic assay development, and bioreagent production. It was founded in 2002 and is based in Costa Mesa, California.

Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.


AngioLogix is a provider of cardiovascular health diagnostics.


CyberGene is a company that operates in the MedTech field. The company's main offerings include diagnostics for prenatal conditions, pregnancy loss, and male infertility. These services primarily cater to the healthcare industry. It was founded in 1995 and is based in Sweden.

Sober Steering Logo
Sober Steering

Sober Steering, now part of Edu Autos, operates in the automotive technology sector. The company's primary product is a biosensor system embedded in a vehicle's steering wheel that non-invasively detects ethanol in the driver's bloodstream to diagnose intoxication and prevent drunk driving by immobilizing the vehicle if necessary. This technology primarily targets the automotive industry. It was founded in 2009 and is based in Boca Raton, Florida.

Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.